MARKET

AVBP

AVBP

Arrivent Biopharma Inc
NASDAQ
30.00
-1.46
-4.64%
After Hours: 30.00 0 0.00% 19:34 08/13 EDT
OPEN
30.73
PREV CLOSE
31.46
HIGH
30.96
LOW
29.40
VOLUME
478.87K
TURNOVER
--
52 WEEK HIGH
35.83
52 WEEK LOW
16.10
MARKET CAP
1.48B
P/E (TTM)
-8.5218
1D
5D
1M
3M
1Y
5Y
1D
ArriVent BioPharma Is Maintained at Buy by Citigroup
Dow Jones · 3h ago
ArriVent BioPharma Price Target Cut to $40.00/Share From $43.00 by Citigroup
Dow Jones · 3h ago
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40
Benzinga · 3h ago
Analysts Conflicted on These Healthcare Names: ArriVent BioPharma, Inc. (AVBP), Zimmer Biomet Holdings (ZBH) and Tecan Group AG (OtherTCHBF)
TipRanks · 7h ago
ArriVent BioPharma Price Target Maintained With a $45.00/Share by Guggenheim
Dow Jones · 9h ago
Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target
Benzinga · 9h ago
Truist Financial Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
TipRanks · 11h ago
Oppenheimer Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
TipRanks · 11h ago
More
About AVBP
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 is a Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4.

Webull offers Arrivent Biopharma Inc stock information, including NASDAQ: AVBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVBP stock methods without spending real money on the virtual paper trading platform.